Virtu Financial LLC Takes $662,000 Position in Illumina, Inc. $ILMN

Virtu Financial LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 5,046 shares of the life sciences company’s stock, valued at approximately $662,000.

Several other large investors also recently bought and sold shares of the business. Capital World Investors raised its stake in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares in the last quarter. State Street Corp grew its stake in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after buying an additional 130,139 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after buying an additional 1,352,731 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 0.3%

ILMN opened at $161.38 on Tuesday. The stock has a market cap of $24.42 billion, a price-to-earnings ratio of 29.34, a P/E/G ratio of 3.03 and a beta of 1.50. The stock’s 50 day moving average price is $145.95 and its 200-day moving average price is $136.45. Illumina, Inc. has a one year low of $88.00 and a one year high of $177.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $0.97 earnings per share. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ILMN. Evercore restated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Royal Bank Of Canada started coverage on Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target on the stock. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Barclays boosted their price objective on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $142.12.

Insider Buying and Selling

In other news, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 over the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.